Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
Authors
Tapson, Victor F.Decousus, Herve
Pini, Mario
Chong, Beng H.
Froehlich, James B.
Monreal, Manuel
Spyropoulos, Alex C.
Merli, Geno J.
Zotz, Rainer B.
Bergmann, Jean-Francois
Pavanello, Ricardo
Turpie, Alexander G. G.
Nakamura, Mashio
Piovella, Franco
Kakkar, Ajay K.
Spencer, Frederick A.
Fitzgerald, Gordon
Anderson, Frederick A. Jr.
IMPROVE Investigators
UMass Chan Affiliations
Department of Medicine, Division of Cardiovascular MedicineCenter for Outcomes Research
Document Type
Journal ArticlePublication Date
2007-09-19Keywords
Acute DiseaseAged
Anticoagulants
Female
Fibrinolytic Agents
Hospitalization
Humans
Intermittent Pneumatic Compression Devices
Male
Middle Aged
Physician's Practice Patterns
*Registries
Risk Factors
Thromboembolism
Venous Thrombosis
Cardiovascular Diseases
Health Services Research
Metadata
Show full item recordAbstract
BACKGROUND: Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis. Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). METHODS: IMPROVE is an ongoing, multinational, observational study. Participating hospitals enroll the first 10 consecutive eligible acutely ill medical patients each month. Patient management is determined by the treating physicians. An analysis of data on VTE prophylaxis practices is presented. RESULTS: From July 2002 to September 30, 2006, 15,156 patients were enrolled from 52 hospitals in 12 countries, of whom 50% received in-hospital pharmacologic and/or mechanical VTE prophylaxis. In the United States and other participating countries, 52% and 43% of patients, respectively, should have received prophylaxis according to guideline recommendations from the American College of Chest Physicians (ACCP). Only approximately 60% of patients who either met the ACCP criteria for requiring prophylaxis or were eligible for enrollment in randomized clinical trials that have shown the benefits of pharmacologic prophylaxis actually received prophylaxis. Practices varied considerably. Intermittent pneumatic compression was the most common form of medical prophylaxis utilized in the United States, although it was used very rarely in other countries (22% vs 0.2%, respectively). Unfractionated heparin was the most frequent pharmacologic approach used in the United States (21% of patients), with low-molecular-weight heparin used most frequently in other participating countries (40%). There was also variable use of elastic stockings in the United States and other participating countries (3% vs 7%, respectively). CONCLUSIONS: Our data suggest that physicians' practices for providing VTE prophylaxis to acutely ill hospitalized medical patients are suboptimal and highlight the need for improved implementation of existing evidence-based guidelines in hospitals.Source
Chest. 2007 Sep;132(3):936-45. Epub 2007 Jun 15. Link to article on publisher's siteDOI
10.1378/chest.06-2993Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27301PubMed ID
17573514Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1378/chest.06-2993